Teladoc Health (NYSE:TDOC) Price Target Raised to $12.00 at Barclays

Teladoc Health (NYSE:TDOC) had its target price hoisted by Barclays from $10.00 to $12.00 in a research note issued to investors on Thursday, Benzinga reports. Barclays currently has an overweight rating on the health services provider’s stock.

TDOC has been the subject of several other reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research report on Thursday, August 1st. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 price target on shares of Teladoc Health in a research note on Tuesday, August 20th. Royal Bank of Canada boosted their price objective on Teladoc Health from $9.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Oppenheimer decreased their price objective on Teladoc Health from $21.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a report on Friday, August 2nd. Fourteen research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $11.97.

Teladoc Health Trading Up 2.3 %

NYSE:TDOC opened at $9.21 on Thursday. The stock has a 50-day simple moving average of $8.48 and a 200-day simple moving average of $9.66. The stock has a market cap of $1.58 billion, a P/E ratio of -1.60 and a beta of 0.90. Teladoc Health has a 1 year low of $6.76 and a 1 year high of $22.54. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.10. The business had revenue of $640.51 million during the quarter, compared to analysts’ expectations of $630.50 million. Teladoc Health had a negative return on equity of 9.40% and a negative net margin of 37.91%. As a group, analysts anticipate that Teladoc Health will post -1.18 earnings per share for the current fiscal year.

Insider Activity

In other Teladoc Health news, Director Thomas Mckinley purchased 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were purchased at an average cost of $7.57 per share, for a total transaction of $52,990.00. Following the completion of the purchase, the director now directly owns 31,077 shares in the company, valued at $235,252.89. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Thomas Mckinley acquired 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were purchased at an average price of $7.57 per share, with a total value of $52,990.00. Following the completion of the acquisition, the director now owns 31,077 shares in the company, valued at approximately $235,252.89. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Stephany Verstraete sold 15,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $7.60, for a total transaction of $114,000.00. Following the transaction, the chief marketing officer now owns 45,158 shares in the company, valued at $343,200.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,051 shares of company stock valued at $257,565 in the last three months. 0.95% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TDOC. Signaturefd LLC grew its stake in Teladoc Health by 148.7% in the 2nd quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock valued at $28,000 after acquiring an additional 1,715 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Teladoc Health in the second quarter valued at approximately $29,000. SageView Advisory Group LLC purchased a new position in shares of Teladoc Health during the 1st quarter worth approximately $48,000. Covestor Ltd raised its position in shares of Teladoc Health by 58.1% during the 1st quarter. Covestor Ltd now owns 3,817 shares of the health services provider’s stock worth $57,000 after purchasing an additional 1,403 shares during the last quarter. Finally, Blue Trust Inc. raised its position in shares of Teladoc Health by 84.5% during the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock worth $40,000 after purchasing an additional 1,854 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.